AlphaCentric Advisors’s GSK GSK Stock Holding History

AlphaCentric Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,000	Closed	-$1.43M	–	246
2024 Q3	$1.43M	Hold	35,000	–	–	1.06%	31
2024 Q2	$1.35M	Hold	35,000	–	–	0.99%	32
2024 Q1	$1.5M	Hold	35,000	–	–	0.91%	38
2023 Q4	$1.3M	Sell	35,000 -15,000	-30%	-$538K	0.87%	42
2023 Q3	$1.81M	Hold	50,000	–	–	1.03%	31
2023 Q2	$1.78M	Sell	50,000 -30,000	-38%	-$1.08M	0.99%	35
2023 Q1	$2.85M	Buy	80,000 +19,000	+31%	+$665K	1.96%	7
2022 Q4	$2.14M	Sell	61,000 -9,000	-13%	-$300K	2.12%	4
2022 Q3	$2.06M	Buy	+70,000	New	+$2.65M	2.11%	8
2021 Q2	–	Sell	-8,000	Closed	-$357K	–	224
2021 Q1	$357K	Buy	8,000 +6,320	+376%	+$287K	0.12%	65
2020 Q4	$77K	Buy	1,680 +1,520	+950%	+$69.8K	0.03%	158
2020 Q3	$8K	Hold	160	–	–	﹤0.01%	159
2020 Q2	$8K	Buy	+160	New	+$8.21K	﹤0.01%	138

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AlphaCentric Advisors's GSK Position: Q4 2024 in Review

AlphaCentric Advisors sold out of GSK (GSK) in Q4 2024, closing a stake of 35,000 shares — an estimated $1.43M sold.

AlphaCentric Advisors first reported a position in GSK in Q2 2020 and held it in 13 quarters. The position peaked at $2.85M in Q1 2023. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

AlphaCentric Advisors reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 35,000 GSK shares in Q4 2024, an estimated $1.43M.
AlphaCentric Advisors first reported a position in GSK in Q2 2020 and held it in 13 quarters.
AlphaCentric Advisors's GSK position peaked at $2.85M in Q1 2023.
848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.